Revvity Inc. (NYSE:RVTY) Stock Has Average Target Price of $124.43

Revvity Inc. (NYSE:RVTY) has received an average rating of “Hold” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $124.43.

Several brokerages have commented on RVTY. KeyCorp increased their price target on shares of Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Royal Bank Of Canada started coverage on shares of Revvity in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price objective for the company. William Blair initiated coverage on shares of Revvity in a report on Monday, October 5th. They issued an “outperform” rating for the company. Weiss Ratings raised shares of Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, UBS Group assumed coverage on shares of Revvity in a research note on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price target on the stock.

Revvity Stock Up 0.2%

RVTY stock opened at $165.66 on Tuesday. The company’s 50 day moving average price is $143.88 and its 200 day moving average price is $111.88. The firm has a market capitalization of $18.49 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 3.01 and a beta of 1.06. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $169.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Revvity will post 5.36 EPS for the current fiscal year.

Insider Activity

In related news, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the transaction, the insider owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Tajinder Vohra sold 7,330 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares of the company’s stock, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,045 shares of company stock valued at $1,281,439 in the last quarter. Insiders own 0.85% of the company’s stock.

Institutional Trading of Revvity

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. grew its holdings in Revvity by 35.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 67,485 shares of the company’s stock valued at $10,318,000 after purchasing an additional 17,629 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Revvity in the third quarter valued at about $5,522,000. ProShare Advisors LLC raised its position in shares of Revvity by 1.1% during the 3rd quarter. ProShare Advisors LLC now owns 21,941 shares of the company’s stock valued at $3,355,000 after acquiring an additional 232 shares in the last quarter. Vise Technologies Inc. bought a new stake in Revvity in the 3rd quarter valued at about $262,000. Finally, State of Wyoming bought a new stake in shares of Revvity during the 3rd quarter worth about $267,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.